Sugi Predict

Sugi Predict / Compounds / SCHEMBL3710686

SCHEMBL3710686

SCHEMBL3710686

Cc1c(Br)cccc1C(=O)Cl

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ HPGD P15428 4/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ PRNP P04156 1/20 0.37
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ HSP90AA1 P07900 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2300929 0.84 ALDH1A1 (0.50) ALDH1A1ALOX15HPGDHSD17B10MEN1
SCHEMBL11089840 0.83 PRNP (0.47) ALDH1A1HPGDHSD17B10SMN1; SMN2PRNP
SCHEMBL29621571 0.81 TSHR (0.52) ALDH1A1ALOX15HPGDHSD17B10SMN1; SMN2
SCHEMBL4443208 0.81 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10SMN1; SMN2PRNP
SCHEMBL6469935 0.81 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10SMN1; SMN2PRNP
SCHEMBL211283 0.81 TSHR (0.52) ALDH1A1ALOX15HPGDHSD17B10SMN1; SMN2
Hydrochloric Acid SCHEMBL15351222 0.79 TSHR (0.50) ALDH1A1ALOX15HPGDHSD17B10SMN1; SMN2
SCHEMBL16357915 0.79 ALDH1A1 (0.39) ALDH1A1HPGDHSD17B10SMN1; SMN2PRNP
SCHEMBL1363612 0.79 METAP2 (0.45) ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL18190399 0.79 P2RX7 (0.50) ALDH1A1HPGDHSD17B10SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 — — US disclosed
EP-4467199-A2 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2024-11-27 — — EP disclosed
CN-118908957-A Small molecule inhibitors of NF- κB induced kinase 詹森药业有限公司 2024-11-08 — — CN disclosed
US-20240285611-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2024-08-29 — — US disclosed
EP-3976597-B1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-08-28 — — EP disclosed
CN-118480001-A C-Kit (V559D)/PDGFR beta double-target allosteric inhibitor and preparation method, pharmaceutical composition and application thereof 贵州省天然产物研究中心 2024-08-13 — — CN disclosed
CN-113072551-B Nitrogen-containing biphenyl derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-08-13 — — CN disclosed
CN-114222737-B Small molecule inhibitors of NF- κB induced kinase 詹森药业有限公司 2024-07-26 — — CN disclosed
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-06-20 — — US disclosed
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 — — US disclosed
WO-2010093930-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL ALLERGAN, INC. (US) 2010-08-19 — — WO disclosed
EP-1385856-A2 AMINO ACID COMPLEXES OF C-ARYL GLUCOSIDES FOR TREATMENT OF DIABETES AND METHOD Bristol-Myers Squibb Company (US) 2004-02-04 — — EP disclosed
WO-2002083066-A2 AMINO ACID COMPLEXES OF C-ARYL GLUCOSIDES FOR TREATMENT OF DIABETES AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-24 — — WO disclosed
CN-1031378-C Combating insect infestation in rice ROHM & HAAS (US) 1996-03-27 — — CN disclosed
CN-1030911-C Dibenzoylalkylcyanohydrazines ROHM & HAAS (US) 1996-02-07 — — CN disclosed
EP-0461809-B1 Dibenzoylalkylcyanohydrazines ROHM & HAAS (US) 1994-12-07 — — EP disclosed
US-5117057-A Insecticidal N' substituted-N-N'-disubstituted-hydrazines ROHM AND HAAS COMPANY (US) 1992-05-26 — — US disclosed
CN-1057452-A Dibenzoyl alkyl-alkyl cyanides ROHM & HAAS (US) 1992-01-01 — — CN disclosed
EP-0461809-A1 Dibenzoylalkylcyanohydrazines ROHM AND HAAS COMPANY (US) 1991-12-18 — — EP disclosed
CN-1046835-A Go out and remove the method for rice insect pest ROHM & HAAS (US) 1990-11-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase NFKBIA, IKBKB, NFRKB ALDH1A1 4109/4885ALOX15 904/4885HPGD 726/4885
US-20240285611-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BAX, BCL2, BCL3 ALDH1A1 4319/4885ALOX15 977/4885HPGD 1594/4885
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG ALDH1A1 3824/4885ALOX15 1908/4885HPGD 1972/4885
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, IKBKE ALDH1A1 4012/4885ALOX15 815/4885HPGD 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.